Zelira Therapeutics Limited
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment o… Read more
Market Cap & Net Worth: Zelira Therapeutics Limited (ZLDAF)
Zelira Therapeutics Limited (OTCQB:ZLDAF) has a market capitalization of $3.57 Million ($3.57 Million) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #34451 globally and #11231 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zelira Therapeutics Limited's stock price $0.30 by its total outstanding shares 11897155 (11.90 Million).
Zelira Therapeutics Limited Market Cap History: 2017 to 2025
Zelira Therapeutics Limited's market capitalization history from 2017 to 2025. Data shows change from $154.07 Million to $3.57 Million (-32.28% CAGR).
Zelira Therapeutics Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zelira Therapeutics Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5437.14x
Zelira Therapeutics Limited's market cap is 5437.14 times its annual revenue
1728.56x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $46.85 Million | $663.32K | -$8.55 Million | 70.62x | N/A |
| 2022 | $8.47 Million | $1.54 Million | -$11.95 Million | 5.50x | N/A |
| 2023 | $7.01 Million | $301.12K | -$5.57 Million | 23.29x | N/A |
| 2024 | $5.35 Million | $94.95K | -$36.57 Million | 56.38x | N/A |
| 2025 | $3.57 Million | $656.00 | -$3.63 Million | 5437.14x | N/A |
Competitor Companies of ZLDAF by Market Capitalization
Companies near Zelira Therapeutics Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Zelira Therapeutics Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Zelira Therapeutics Limited Historical Marketcap From 2017 to 2025
Between 2017 and today, Zelira Therapeutics Limited's market cap moved from $154.07 Million to $ 3.57 Million, with a yearly change of -32.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $3.57 Million | -33.38% |
| 2024 | $5.35 Million | -23.68% |
| 2023 | $7.01 Million | -17.23% |
| 2022 | $8.47 Million | -81.91% |
| 2021 | $46.85 Million | -64.29% |
| 2020 | $131.17 Million | +43.18% |
| 2019 | $91.61 Million | +25.71% |
| 2018 | $72.87 Million | -52.70% |
| 2017 | $154.07 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Zelira Therapeutics Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.57 Million USD |
| MoneyControl | $3.57 Million USD |
| MarketWatch | $3.57 Million USD |
| marketcap.company | $3.57 Million USD |
| Reuters | $3.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.